Articles

The Flemingsberg Science Foundation is a neutral actor in the regional development of southern Stockholm, with a mission to promote and spearhead the development of knowledge-intensive activities in Flemingsberg. Part of Flemingsberg Science is the Life Science Cluster Flemingsberg, an ERDF project aimed at fostering growth in the life sciences. Read more about the initiative here. In Flemingsberg…

Sprint Bioscience summarizes below the company’s upcoming meetings with potential partners and investors during the second half of 2026. The list is subject to change and is available on the company’s website. International partnering conferences: September 8–9, 2026 Nordic Life Science Days, Stockholm, Sweden https://nlsdays.com/ September 14–16, 2026 IPLS, International Partnering in Life Science Society Annual Conference, Stockholm, Sweden, https://ipls.online/events/, October 7–9, 2026, Bio Japan, Yokohama, Japan, https://jcd-expo.jp/en/, November 9–11 […]

Sprint Bioscience announced in a press release on July 23 that the company has entered into an agreement with Lilly TuneLab, a collaborative, AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining TuneLab, Sprint Bioscience intends to strengthen and accelerate the development of its portfolio through access to advanced models for…

Sprint Bioscience summarizes below the company's upcoming meetings with potential partners and investors in spring 2026. The list may be updated. Scientific conference: International partnering conferences: For investors: Current calendar and recorded presentations from the investor meetings can be viewed here: https://sprintbioscience.com/sv/kalender/https://sprintbioscience.com/sv/film/

On January 12-15, Sprint Bioscience will be present at J.P. Morgan Healthcare Week, the most important meeting place of the year for the global life science industry. Leading players gather here for a week filled with partnering, investor meetings and groundbreaking ideas. For Sprint Bioscience, this is a unique opportunity to present preclinical drug programs and make strategic contacts. In an interview...

Sprint Bioscience has sold one of its cancer programs, TREX1, to Gilead Sciences, Inc. The deal includes an upfront payment of USD 14 million and potential milestone payments related to clinical, regulatory and commercial progress, which could total up to USD 400 million. Read more about the deal in the press release from November 24 or in one of the news articles...

Sprint Bioscience has entered into a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore to expand Sprint Bioscience's MASH (Metabolic dysfunction-associated steatohepatitis) program into inflammatory diseases. Under the collaboration, compounds developed by Sprint Bioscience in the program will be evaluated by EDDC - Singapore's national platform for drug discovery and development and part of the...

In our work to develop small-molecule preclinical drug candidates that can contribute to new cancer therapies, speed and precision are crucial. By collaborating with SciLifeLab's Drug Discovery and Development (DDD) Platform, we gain access to advanced protein quality analysis - a key component of our fragment-based drug development. This infrastructure enables us to...

On April 8, the subscription period for Sprint Bioscience's rights issue began. The subscription rights are traded on First North Premier Growth Market until April 17, 2025, and the subscription period continues until April 24, 2025. More information can be found here. Read BioStock's interview (in Swedish) with CEO Johan Emilsson about the ongoing rights issue. See the latest Company Presentation, in the studio at [...]

Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: September 18-19: Nordic Life Science Days, Malmö, Sweden October 8-9: LSX Nordic Congress, Copenhagen, Denmark November 4-6: BIO-Europe Stockholm, Sweden November 20-21: BioStock Life Science Summit

The Bio International Convention partnering conference was held June 3-6 in San Diego, California. Sprint Biosciences CEO Johan Emilsson was there. What general impressions do you take home from the conference? "It is almost always high pressure at this conference. It is one of the largest and most prestigious partnering conferences in biotechnology and drug development with...

Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: March 18-20, 2024: BIO-Europe Spring, Barcelona, Spain April 29-30, 2024: LSX World Congress, London, England June 3-6, 2024: BIO International Convention, San Diego, USA